Genotyping of Patients with Adverse Drug Reaction or Therapy Failure: Database Analysis of a Pharmacogenetics Case Series Study.
Anna BollingerCéline K StäubleChiara JeizinerFlorine M WissHersberger KurtMarkus L LampertHenriette E Meyer Zu SchwabedissenAllemann SamuelPublished in: Pharmacogenomics and personalized medicine (2023)
The data analysis from this study provides valuable insights for the main focus of further research in the context of PGx. The results indicate that most of the selected patients in our sample represent suitable target groups for PGx panel testing in clinical practice, notably those taking drugs for mental or behavioral disorder, circulatory diseases, immunological diseases, pain-related diseases, and patients experiencing polypharmacy.
Keyphrases
- end stage renal disease
- adverse drug
- data analysis
- ejection fraction
- clinical practice
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- chronic pain
- mental health
- stem cells
- high throughput
- neuropathic pain
- mesenchymal stem cells
- spinal cord
- electronic health record
- smoking cessation
- patient reported